Replies to post #2761 on Biotech Values

[rkrw]

Putting aside squalamine potential 5 years out, just wondering where the eyet data is so much better? Would appreciate any pointer.

P.S. You should have seen the recent leh comments on vegf-trap. "...VEGF-TRAP appeared thus far to be one of the
less promising emerging molecularly targeted drugs at ASCO."
Ouch :-)